{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=45",
    "query": {
      "intervention": "cohort 1",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 8005,
    "total_pages": 801,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=46&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+1&page=44&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T16:38:24.344Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02304393",
      "title": "A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Selicrelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2014-12-12",
      "completion_date": "2019-11-07",
      "has_results": false,
      "last_update_posted_date": "2019-12-13",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02304393"
    },
    {
      "nct_id": "NCT01549314",
      "title": "Cystic Fibrosis Related Bone Disease: the Role of CFTR",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis Related Bone Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "6 Years to 75 Years"
      },
      "enrollment_count": 79,
      "start_date": "2012-04",
      "completion_date": "2020-02",
      "has_results": true,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01549314"
    },
    {
      "nct_id": "NCT02833506",
      "title": "Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IIA Fallopian Tube Cancer",
        "Stage IIA Ovarian Cancer",
        "Stage IIB Fallopian Tube Cancer",
        "Stage IIB Ovarian Cancer",
        "Stage IIC Fallopian Tube Cancer",
        "Stage IIC Ovarian Cancer",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Recombinant NY-ESO-1 Protein",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2017-12-08",
      "completion_date": "2019-08-15",
      "has_results": false,
      "last_update_posted_date": "2018-05-01",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833506"
    },
    {
      "nct_id": "NCT01153906",
      "title": "Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Infections, Papillomavirus"
      ],
      "interventions": [
        {
          "name": "Data collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "9 Years to 25 Years · Female only"
      },
      "enrollment_count": 1516,
      "start_date": "2010-10",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-12-02",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01153906"
    },
    {
      "nct_id": "NCT06860633",
      "title": "Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Myasthenia Gravis Crisis",
        "Myasthenia Gravis Exacerbations",
        "AChR Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Efgartigimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-03-06",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06860633"
    },
    {
      "nct_id": "NCT05809752",
      "title": "A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leptomeningeal Disease",
        "Triple Negative Breast Cancer",
        "HER2-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2023-08-22",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05809752"
    },
    {
      "nct_id": "NCT05347992",
      "title": "ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "DxTerity Diagnostics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 423,
      "start_date": "2022-05-03",
      "completion_date": "2023-08-17",
      "has_results": false,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 1,
      "location_summary": "Compton, California",
      "locations": [
        {
          "city": "Compton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05347992"
    },
    {
      "nct_id": "NCT05757492",
      "title": "Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "CHS-006 (anti-TIGIT)",
          "type": "DRUG"
        },
        {
          "name": "toripalimab (anti-PD-1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Coherus Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2023-04-26",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Detroit, Michigan • Reno, Nevada + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757492"
    },
    {
      "nct_id": "NCT02794571",
      "title": "Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Tumors"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 518,
      "start_date": "2016-05-23",
      "completion_date": "2024-11-13",
      "has_results": false,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02794571"
    },
    {
      "nct_id": "NCT06393387",
      "title": "Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hiv",
        "HIV-1-infection",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG/3TC versus BIC/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Midway Specialty Care Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2024-06-01",
      "completion_date": "2025-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-11-19T16:38:24.344Z",
      "location_count": 1,
      "location_summary": "West Palm Beach, Florida",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06393387"
    }
  ]
}